DLA Piper represented NuVasive, Inc. (NASDAQ: NUVA), a San Diego-based medical device company that creates and distributes products for surgical treatment of spine disorders, in its recent acquisition of Simplify Medical, a privately held company and developer of the Simplify Cervical Artificial Disc for cervical total disc replacement (cTDR).
With the acquisition of Simplify Medical, NuVasive is now able to address all key segments of the cervical spine by offering comprehensive, procedurally integrated solutions across anterior cervical discectomy and fusion (ACDF), posterior cervical fusion (PCF) and cTDR procedures.
“It was a pleasure to bring to bear our wide-ranging life sciences M&A experience to complete this acquisition for NuVasive, which will expand its portfolio significantly and ensure it can continue to provide world-class medical technology that improves the standard of care for patients around the world,” said Larry Nishnick, the DLA Piper partner who led the firm’s deal team.
In addition to Nishnick (San Diego), the DLA Piper team advising NuVasive included corporate associate Kevin Berggren (San Diego) and a number of other lawyers at the firm. The corporate team of Grant Koch and Jake Thornton of DLA Piper (Australia) also provided valuable assistance in the transaction.
With more than 1,000 corporate lawyers globally, DLA Piper helps clients execute complex cross-border transactions seamlessly while supporting clients across all stages of development. The firm has been rated number one in global M&A volume for 11 consecutive years, according to Mergermarket.
DLA Piper advises on all aspects of the life sciences sector, combining subject matter experience with considerable knowledge of the scientific, medical, regulatory, commercial and enforcement environments facing biopharmaceutical, medical device, research and diagnostics clients. Recognizing that clients’ needs vary, the firm rapidly organizes and customizes client service teams, whether for a large pharmaceutical company, a mid-sized medical device client or a development-stage biotech company.
